Cardiovascular drug development using radiopharmaceuticals

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 935-942

  Ukkonen, Heikki ^a,b   Yoshinaga, Keiichiro ^c   DaSilva, Jean N ^d   Beanlands, Rob S B ^d   Knuuti, Juhani ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ACETIC ACID C 11; ADENOSINE RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOSIMENDAN; METOPROLOL; MUSCARINIC RECEPTOR; PALMITIC ACID C 11; PLACEBO; RADIOPHARMACEUTICAL AGENT; TRIMETAZIDINE; DIAGNOSTIC AGENT; RADIOISOTOPE;

ADRENERGIC SYSTEM; AEROBIC METABOLISM; AUTONOMIC NERVOUS SYSTEM; CARDIAC RESYNCHRONIZATION THERAPY; CELL HOMING; CELL LABELING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG HALF LIFE; DRUG RESEARCH; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PERFUSION; HEART SCINTISCANNING; HEART WORK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP APNEA SYNDROME; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; METHODOLOGY; PATHOPHYSIOLOGY; PHARMACEUTICS; SCINTISCANNING; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 65549139356     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582011     Document Type: Review

References (91)

1. Frank R. Nuclear bioimaging in drug development and regulatory review. J Clin Pharmacol 1999; 39: 51S-5.
2. Gradnik R. Drug design in cardiology: the pharmaceutical industry point of view. In: Comar D, Ed. Positron emission tomography for drug development and evaluation. Dordrecht: Kluwer 1995: 215-8.
3. Opie LH. In: Opie LH, Ed, The Heart. Physiology, from cell to circulation. Philadelphia: Lippincott Raven Publishers, 1998; 295-341.
4. DeGrado TR, Coenen HH, Stöcklin G. 14(R,S) [18F]fluoro 6 thia heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med 1991; 32: 1888-96.
5. Stone CK, Pooley RA, DeGrado TR, Renstrom B, Nickles RJ, Nellis SH, et al. Myocardial uptake of the fatty acid analog 14 fluorine 18 fluoro 6 thia heptadecanoic acid in comparison to beta oxidation rates by tritiated palmitate. J Nucl Med 1998; 39: 1690-6.
6. Iida H, Rhodes CG, Araujo LI, Yamamoto Y, de Silva R, Maseri A, et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Circulation 1996; 94: 792-807.
7. Beanlands RS, Schwaiger M. Changes in myocardial oxygen consumption and efficiency with heart failure therapy measured by 11C acetate PET. Can J Cardiol 1995; 11: 293-300.
8. Pietila M, Malminiemi K, Ukkonen H, Saraste M, Nagren K, Lehikoinen P, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med 2001; 28: 373-6.
9. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004; 11: 603-16.
10. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 1997; 96: 3416-22.
11. Kies P, Wichter T, Schafers M, Paul M, Schafers KP, Eckardt L, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation. 2004; 110: 3017-22.
12. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 2006; 47: 1172-80.
13. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
14. Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des 2007; 13: 17-31.
15. Botti C, Negri DR, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med 1997; 24: 497-504.
16. Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM. 18FFDG labelling of human leukocytes. Nucl Med Commun 2000; 21: 691-4.
17. Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: imaging properties of 18FFDG-labeled white blood cells versus 18F-FDG. J Nucl Med 2005; 46: 1522-30.
18. Rini JN, Bhargava KK, Tronco GG, Singer C, Caprioli R, Marwin SE, et al. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology 2006; 238: 978-87.
19. Qian H, Yang Y, Huang J, Gao R, Dou K, Yang G, et al. Intracoronary delivery of autologous bone marrow mononuclear cells radiolabeled by 18F-fluoro-deoxy-glucose: Tissue distribution and impact on post-infarct swine hearts. J Cell Biochem 2007; 102: 64-74.
20. Ma B, Hankenson KD, Dennis JE, Caplan AI, Goldstein SA, Kilbourn MR. A simple method for stem cell labeling with fluorine 18. Nucl Med Biol 2005; 32: 701-5.
21. Bruskin A, Sivaev I, Persson M, Lundqvist H, Carlsson J, Sjoberg S, et al. Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closododecaborate (Bromo-DABI). Nucl Med Biol 2004; 31: 205-11.
22. Ellis BL, Sharma HL. Co, Fe and Ga chelates for cell labelling: a potential use in PET imaging? Nucl Med Commun 1999; 20: 1017-21.
23. Vassaux G, Groot-Wassink T. In vivo noninvasive imaging for gene therapy. J Biomed Biotechnol 2003; 2003: 92-101.
24. Zhang Y, Ruel M, Beanlands R, deKemp RA, Suuronen EJ, DaSilva JN. Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography. Current Pharmaceutical Design, 2008, 14,
25. Knuuti J, Kalliokoski R, Janatuinen T, Hannukainen J, Kalliokoski KK, Koskenvuo J, et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648-52.
26. Ling MC, Ruddy TD, deKemp RA, Ukkonen H, Duchesne L, Higginson L, et al. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 2005; 149: 1137.e9-e16.
27. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561-8.
28. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airakinen KEJ, et al. J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006; 114: 2130-7.
29. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therepeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12
30. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazine on ischemic left ventricular dysfunction in patients with coronary heart disease. Am J Cardiol 1998; 82: 898-90.
31. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al. J. The effect of Trimetazidine, a metabolic modulator, on cardiac function and substrate metabolism in idiopathic dilated cardiomyopathy. Circulation 2008; 118: 1250-8.
32. Beanlands RSB, Nahmias C, Gordon I, Coates G, deKemp R, Firnau G, et al. The effects of β1 blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction. A double blind, placebo controlled, positron emission tomography study. Circulation 2000; 102: 2070-5.
33. Haikala H, Linden IB. Mechanism of action of calcium sensitizing drugs. J Cardiovasc Pharmacol 1995; 26: S10-S19.
34. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Någren K, et al. Myocardial efficiency during calcium-sensitization with levosimendan. A noninvasive study employing positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596-607.
35. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68: 522-31.
36. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med 1992; 33: 471-7.
37. Ungerer M, Hartmann F, Karoglan M, Chlistalla A, Ziegler S, Richardt G, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998; 97: 174-80.
38. Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Van Eck-Smit BL, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005; 28: 304-10.
39. Nishioka SA, Martinelli Filho M, Brandão SC, Giorgi MC, Vieira ML, Costa R, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 2007; 14: 852-9.
40. Vanoverschelde J-LJ, Wins W, Essamri B, Bol A, Robert A, Labar D, et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal heart: effects of dobutamine. Am J Physiol 1993; 265: H1884-H1892.
41. Beanlands RSB, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using C-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993; 22: 1389-98.
42. Nelson GS, Berger RD, Fetics BJ, Talbot M, Spinelli JC, Hare JM, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000; 102: 3053-9.
43. Ukkonen H, Beanlands R, MD, Burwash I, de Kemp R, Nahmias C, et al. The effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation 2003; 107: 28-31.
44. Sundell J, Engblom E, Koistinen J, Ylitalo A, Naum A, Stolen K, et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2004; 43: 1027-33.
45. Knuuti J, Sundell J, Naum A, Engblom E, Koistinen J, Ylitalo A, et al. Assessment of right ventricular oxidative metabolism by PET in patients with idiopathic dilated cardiomyopathy undergoing cardiac resynchronization therapy. Eur J Nucl Med Mol Imaging 2004; 31: 1592-8.
46. Braunschweig F, Sörensen J, von Bibra H, Olsson A, Rydén L, Långström B, et al. Effects of biventricular pacing on myocardial blood flow and oxygen consumption using carbon-11 acetate positron emission tomography in patients with heart failure. Am J Cardiol 2003; 92: 95-9.
47. Lindner O, Sorensen J,Vogt J, Fricke E, Baller D, Horstkotte D, et al. Cardiac efficiency and oxygen consumption measured with 11C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med 2006; 47: 378-83.
48. Yoshinaga K, Burwash IG, Leech JA, Haddad H, Johnson C, deKemp RA, et al. The effects of continuous positive airway pressure on myocardial energetics in patients with heart failure and obstructive sleep apnea. J Am Coll Cardiol 2007; 49: 450-8.
49. Bradley TD, Floras JS. Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation 2003; 107: 1671-8.
50. Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, et al. Simultaneous PET and MR imaging. Phys Med Biol 1997; 42: 1965-70.
51. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20.
52. Chin BB, Nakamoto Y, Bulte JW, Pittenger MF, Wahl R, Kraitchman DL. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun 2003; 24: 1149-54.
53. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003; 107: 2134-9.
54. Zhou R, Thomas DH, Qiao H, Bal HS, Choi SR, Alavi A, et al. In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med 2005; 46: 816-22.
55. Qi Y. Optimized collimator designs for small animal SPECT imaging with a compact gamma camera. Conf Proc IEEE Eng Med Biol Soc 2005; 2: 1780-2.
56. Dobrucki LW, Sinusas AJ. Imaging angiogenesis. Curr Opin Biotechnol 2007; 18: 90-6.
57. Simonova M, Shtanko O, Sergeyev N, Weissleder R, Bogdanov A, Jr. Engineering of technetium-99m-binding artificial receptors for imaging gene expression. J Gene Med 2003; 5: 1056-66.
58. Acton PD, Zhou R. Imaging reporter genes for cell tracking with PET and SPECT. Q J Nucl Med Mol Imaging 2005; 49: 349-60.
59. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2: 118-38.
60. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-80.
61. Wu JC, Chen IY, Sundaresan G, Min JJ, De A, Qiao JH, et al. Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation 2003; 108: 1302-5.
62. Keng FY. Clinical applications of positron emission tomography in cardiology: a review. Ann Acad Med Singapore 2004; 33: 175-82.
63. Herschman HR, MacLaren DC, Iyer M, Namavari M, Bobinski K, Green LA, et al. Seeing is believing: non-invasive, quantitative and repetitive imaging of reporter gene expression in living animals, using positron emission tomography. J Neurosci Res 2000; 59: 699-705.
64. Tseng H, Link JM, Stratton JR, Caldwell JH. Cardiac receptor physiology and its application to clinical imaging: present and future. J Nucl Cardiol 2001; 8: 390-409.
65. Koeppe RA. In: Wahl RL, Ed. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams and Wilkins 2002; 65-99.
66. Elsinga PH, van Waarde A, Jaeggi KA, Schreiber G, Heldoorn M, Vaalburg W. Synthesis and evaluation of (S)-4-(3-(2′-[11C]isopropylamino)- 2-hydroxypropoxy)-2H-benzimidazol-2- one ((S)-[11C]-CGP 12388) and (S)-4-(3-((1′-[18F]-fluoroisopropyl) amino)-2-hydroxypropoxy) -2H- benzimidazol-2-one ((S)-[18F]fluoro-CGP 12388) for visualization of beta-adrenoceptors with positron emission tomography. J Med Chem 1997; 40: 3829-35.
67. Elsinga PH, Doze P, van Waarde A, Pieterman RM, Blanksma PK, Willemsen AT, et al. Imaging of beta-adrenoceptors in the human thorax using (S)-[(11)C]CGP12388 and positron emission tomography. Eur J Pharmacol 2001; 433: 173-6.
68. Hattori Y, Kanno M. Role of alpha1-adrenoceptor subtypes in production of the positive inotropic effects in mammalian myocardium: Implications for the alpha1-adrenoceptor subtype distribution. Life Sci 1998; 62: 1449-53.
69. Pike VW, Law MP, Osman S, Davenport RJ, Rimoldi O, Giardinà D, et al. Evaluation of [11C]GB67, a novel radioligand for imaging myocardial alpha 1-adrenoceptors with positron emission tomography. Eur J Nucl Med 2000; 27: 7-17.
70. Feldman AM. Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation 1993; 87: IV27-34.
71. Dzimiri N. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev 1999; 51: 465-501.
72. Houslay MD, Sullivan M, Bolger GB. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 1998; 44: 225-342.
73. DaSilva JN, Lourenco CM, Wilson AA, Houle S. Syntheses of the phosphodiesterase-4 inhibitors [11C]Ro 20-1724, R-, R/S- and S-[11C]rolipram. J Labelled Cpd Radiopharm 2001; 44: 373-84.
74. Lourenco CM, Houle S, Wilson AA, DaSilva JN. Characterization of R-[11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl Med Biol 2001; 28: 347-58.
75. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143-56.
76. Holschbach MH, Olsson RA. Applications of adenosine receptor ligands in medical imaging by positron emission tomography. Curr Pharm Des 2002; 8: 2345-52.
77. Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, et al. A2A-adenosine receptor reserve for coronary vasodilation. Circulation 1998; 98: 711-8.
78. Stone-Elander S, Thorell JO, Eriksson L, Fredholm BB, Ingvar M. In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-DPET: evaluation as a ligand for the study of adenosine A2A receptors. Nucl Med Biol 1997; 24: 187-91.
79. Ishiwata K, Noguchi J, Wakabayashi S, Shimada J, Ogi N, Nariai T, et al. 11C-labeled KF18446: A potential central nervous system adenosine A2a receptor ligand. J Nucl Med 2000; 41: 345-54.
80. Ishiwata K, Kawamura K, Kimura Y, Oda K, Ishii K. Potential of an adenosine A2A receptor antagonist [11C]TMSX for myocardial imaging by positron emission tomography: A first human study. Ann Nucl Med 2003; 17: 457-62.
81. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991; 84: 482-92.
82. Azevedo ER, Parker JD. Parasympathetic control of cardiac sympathetic activity: Normal ventricular function versus congestive heart failure. Circulation 1999; 100: 274-9.
83. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: An in vivo PET study. Circulation 1997; 96: 3416-22.
84. Delahaye N, Le Guludec D, Dinanian S, Delforge J, Slama MS, Sarda L, et al. Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy. Circulation 2001; 104: 2911-6.
85. Leenen FH, Ruzicka M, Huang BS. The brain and salt-sensitive hypertension. Curr Hypertens Rep 2002; 4: 129-35.
86. Hadizad T, Beanlands RS, Mason S, DaSilva JN. Radiosynthesis of C-11 methylcandesartan and its derivative C-11 TH4 as potential imaging agents for angiotensin II AT1 receptors. J Nucl Med 2008: 49 Supplement 1, p.297P
87. Kim SE, Scheffel U, Szabo Z, Burns HD, Gibson RE, Ravert HT, et al. In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist. J Nucl Med 1996; 37: 307-11.
88. Szabo Z, Kao PF, Burns HD, Gibson RE, Hamill TG, Ravert HT, et al. Investigation of angiotensin II/AT1 receptors with carbon-11-L-159,884: a selective AT1 antagonist. J Nucl Med 1998; 39: 1209-13.
89. Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D. A2A adenosine receptor and its modulators: Overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 2008; 14(15): 1525-52.
90. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res 2008; 65(45): 47-118.
91. Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008; 11(1): 104-10.